Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Cancer Immunotherapy as Part of Precision Clinical Medicine
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Cancer Immunotherapy as Part of Precision Clinical Medicine

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 2096

Special Issue Editors

Prof. Dr. Peter Lang

E-Mail Website
Guest Editor
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany
Interests: cancer immunotherapy; hematology; oncology; stem cell transplantation
Dr. Christo Kole

E-Mail Website
Guest Editor
1. Cardiology Department, Sismanogleio General Hospital of Attica, Marousi, Greece
2. Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Interests: cardiovascular medicine and heart failure; cardio-oncology; heart rhythm abnormalities and molecular basis of arrhythmia; molecular biology and genetic

Special Issue Information

Dear Colleagues,

In the last decade, the significant expansion of therapeutic options has transformed the management of almost all forms of cancer. Immunotherapy refers to a novel approach that enables the human immune system to recognize self and non-self and activate an antitumor response in a more precise way. Recent advances in immunotherapy have been at the forefront of this revolution, leading to viable therapeutic options in previously minimally responsive cancers such as gastric and pancreatic cancer. However, because the microenvironment and genetics of each tumor are distinct, enhancing the effect of immunotherapy requires a sophisticated and individualized approach.

It is thus crucial to understand these mechanisms, identify the patient subgroups that are most likely to benefit from immunotherapy, and determine the clinical characteristics of patients with the lowest risk of developing major adverse events.

Therefore, this Special Issue welcomes the submission of papers that explore the advancement of exploration, enhance our understanding of the tumor microenvironment as a predictive and prognostic marker and provide an in-depth understanding of the genomics of different cancer types in order to develop more precise and effective immunotherapy for cancer.

Prof. Dr. Peter Lang
Dr. Christo Kole
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • immunotherapy
  • tumor microenvironment
  • molecular biology and genetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

30 pages, 838 KB  
Review
Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology
by Eleni Stefanou, Georgios Tsitsinakis, Dimitra Karageorgou and Christo Kole
Cancers 2025, 17(17), 2838; https://doi.org/10.3390/cancers17172838 - 29 Aug 2025
Viewed by 1747
Abstract
Background/Objectives: Cancer immunotherapy has revolutionized the field of oncology by harnessing the immune system to attack cancer cells, increasing survival in a broad spectrum of malignancies. However, despite its positive therapeutic benefit, immunotherapy is also associated with a spectrum of adverse events [...] Read more.
Background/Objectives: Cancer immunotherapy has revolutionized the field of oncology by harnessing the immune system to attack cancer cells, increasing survival in a broad spectrum of malignancies. However, despite its positive therapeutic benefit, immunotherapy is also associated with a spectrum of adverse events affecting various vital organs, including the cardiovascular system. Methods: We conducted a comprehensive review of the available literature on the epidemiology, pathophysiological mechanisms, and current management approaches for cardiovascular adverse events associated with cancer immunotherapy. In addition, we evaluated emerging personalized strategies and interventions aimed at mitigating these risks and improving patient outcomes. Results: Immunotherapy is associated with a broad spectrum of potentially serious cardiovascular adverse events, including immune-mediated myocarditis, heart failure, arrhythmias, pericarditis, and accelerated atherosclerosis. Among these, immune checkpoint inhibitor-associated myocarditis is the most well characterized and potentially fatal form of cardiotoxicity, with reported mortality rates approaching 50%. Similarly, chimeric antigen receptor T-cell therapy, despite its powerful antitumor efficacy, is frequently associated with cytokine release syndrome—a profound immune activation that can lead to significant systemic and cardiovascular complications. In response to these challenges, several personalized strategies are currently under development, including artificial intelligence and machine learning approaches, genetic and transcriptomic profiling, novel biomarker discovery, and integrated risk scoring systems, all aimed at enhancing risk stratification and improving patient care. Conclusions: Cancer immunotherapy has been associated with a range of immune-related cardiac adverse events, both non-severe and severe. As such, it is critically important to adopt a personalized approach to patient management before, during, and after the administration of immunotherapy. Early recognition through heightened clinical vigilance, along with the implementation of individualized risk assessment tools, is essential for identifying patients at high risk of immunotherapy-induced cardiotoxicity. These strategies are imperative for optimizing patient outcomes and ensuring safe and effective cancer treatment. Full article
(This article belongs to the Special Issue Cancer Immunotherapy as Part of Precision Clinical Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop